The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%!
✨ The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%! ✨
multiple myeloma
🌟BCMA (also known as CD269) and GPRC5D, these two targets are revolutionizing the treatment landscape of multiple myeloma (MM). BCMA is one of the hottest targets for treating MM currently, while GPRC5D is poised to be a potent complement to BCMA.
🔍 About BCMA: CAR-T Therapy with Remission Rates Exceeding 90%!
👩⚕️BCMA is primarily expressed on the surface of terminally differentiated B cells, making it a promising new target in hematologic malignancies treatment. Currently, both in clinical trials and marketed BCMA-targeted CAR-T therapies have shown significant efficacy, with some second-generation CAR-T projects achieving remission rates of over 90%, and the remission rates of domestically produced CAR-T products are also leading globally.
Among domestically produced CAR-T therapies in China,
🌟The marketed injection of Cilta-cel (Carvykti) has an overall remission rate of 89.6% and a complete remission rate of 77.1%.
🌟The fully human Equecabtagene Autoleucel injection (developed by the highly regarded Chinese company IASO Bio) boasts an overall remission rate of 98.9%, with a complete remission rate of 82.4%.
🌟Additionally, recent follow-up data from the ASH conference showed that Zevor-cel, developed by Chinese company CARsgen and just approved for market in China, has an overall remission rate of 100%, with a complete remission rate of 92.9%.
💡 About GPRC5D: A New Hopeful Treatment Target!
🔬About 65% of MM patients exhibit high expression of GPRC5D, and its expression is relatively independent of BCMA. The development speed of domestically produced CAR-T projects in China is considerable. For example, OriCAR-017, a CAR-T product developed by a domestic pharmaceutical company, achieved an overall remission rate of 100% in 10 trial patients, with a strict complete remission rate of 60%.
🩺China is rapidly advancing in the field of CAR-T therapy, leading the way in both technological development and clinical applications. In the future, we will witness more “miracles of healing” created by these novel cell therapies.
We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070
#MultipleMyeloma #BCMA #GPRC5D #CART #CellTherapy #MiraclesOfHealing #CARTcell